Latest Franking News

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

WT Financial Group (ASX, WTL) reported a 20.5% rise in FY2025 net profit after tax to $4.6 million, driven by strong revenue growth and operational leverage. The company declared a fully-franked dividend of 0.7 cents per share, underpinned by its expanding B2B financial advice network and proprietary risk management framework.

Solvar Limited reported a robust FY25 with a 17.4% increase in normalised NPAT and launched Bennji, a new commercial lending brand targeting small businesses.

WT Financial Group Limited reported a robust FY2025 with a 17.3% rise in gross revenue and a 20.5% increase in net profit after tax, underpinned by its dominant B2B financial adviser network. The company also announced a fully franked final dividend and a strategic joint venture poised to fuel future growth.

Resimac Group Ltd delivered a robust FY25 performance, marked by strong organic growth in home loans and asset finance, bolstered by the strategic acquisition of Westpac's $1.5 billion auto portfolio. The company raised dividends to 19 cents fully franked, reflecting confidence amid rising impairment expenses.

Resimac Group reported a 13% rise in operating profit for FY25, driven by strong asset growth and a major auto finance acquisition, while declaring a total dividend of 19 cents per share.

Dicker Data Ltd reported a robust 15.7% increase in gross revenue for H1 FY25, driven by AI deployments and accelerated PC refresh cycles. The company also provided confident FY25 guidance amid strategic moves into AI ecosystems and cybersecurity.

Resimac Group Ltd reported a stable FY25 net profit after tax of $34.6 million and declared a fully franked final dividend of 3.5 cents per share, maintaining its steady financial footing amid modest revenue growth.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

Sequoia Financial Group reported a robust FY25 with a 13.7% rise in EBITDA and a 44% jump in funds under advice, underpinned by strategic restructuring and technology investments.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.